Developing EZH2-Targeted Therapy for Lung Cancer

Cancer Discov. 2016 Sep;6(9):949-52. doi: 10.1158/2159-8290.CD-16-0800.

Abstract

Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Disease Models, Animal
  • Drug Discovery
  • Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors*
  • Epigenesis, Genetic / drug effects*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Mice
  • Molecular Targeted Therapy*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Enhancer of Zeste Homolog 2 Protein